Crucell Announces PER.C6® Licensing Agreement with Tibotec

25-Nov-2005

Dutch biotechnology company Crucell N.V. announced that it has signed a PER.C6® license agreement with Ireland-based Tibotec Pharmaceuticals Ltd. The non-exclusive agreement allows Tibotec to use the PER.C6® cell line for research in the field of virology.

Under the terms of the agreement, Tibotec will pay a research license fee, annual maintenance fees and milestone payments. Further financial details were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...